Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

NDA FilingALXN1840Positive

AI Analysis

Summary

Monopar Therapeutics initiated rolling NDA submission to FDA for ALXN1840, a first-in-class albumin tripartite complex activator for Wilson disease treatment, with initial application sections already submitted for review.

Outcome Details

Rolling NDA submission initiated with first sections submitted

Importance:7/10

Sentiment:

0.70

NDAFDA submissionWilson diseasefirst-in-classrolling submission

Related Companies

$MNPR

Read the original article

Published by GlobeNewswire Pharma on July 22, 2026 12:00 PM

Read Original